Zingaropoli, M.A.; Pasculli, P.; Tartaglia, M.; Dominelli, F.; Ciccone, F.; Taglietti, A.; Perri, V.; Malimpensa, L.; Ferrazzano, G.; Iannetta, M.;
et al. Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk. Biology 2023, 12, 587.
https://doi.org/10.3390/biology12040587
AMA Style
Zingaropoli MA, Pasculli P, Tartaglia M, Dominelli F, Ciccone F, Taglietti A, Perri V, Malimpensa L, Ferrazzano G, Iannetta M,
et al. Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk. Biology. 2023; 12(4):587.
https://doi.org/10.3390/biology12040587
Chicago/Turabian Style
Zingaropoli, Maria Antonella, Patrizia Pasculli, Matteo Tartaglia, Federica Dominelli, Federica Ciccone, Ambra Taglietti, Valentina Perri, Leonardo Malimpensa, Gina Ferrazzano, Marco Iannetta,
and et al. 2023. "Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk" Biology 12, no. 4: 587.
https://doi.org/10.3390/biology12040587
APA Style
Zingaropoli, M. A., Pasculli, P., Tartaglia, M., Dominelli, F., Ciccone, F., Taglietti, A., Perri, V., Malimpensa, L., Ferrazzano, G., Iannetta, M., Del Borgo, C., Lichtner, M., Mastroianni, C. M., Conte, A., & Ciardi, M. R.
(2023). Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk. Biology, 12(4), 587.
https://doi.org/10.3390/biology12040587
